Astellas and Pfizer Report Results of Xtandi (enzalutamide) in P-III PROSPER Study for Non-Metastatic Castration-Resistant Prostate Cancer
Shots:
- The P-III PROSPER study involves assessing of Xtandi (160mg- QD) + ADT vs PBO + ADT in 1400 patients with nmCRPC across the US- EU- SA- Canada- and the Asia-Pacific region
- The P-III PROSPER study resulted in meeting its 2EPs i.e. improvement in the OS. In 2018- the study met its 1EPs of MFS- which is included in Xtandi’s label in the US- EU- Japan & is currently under review in China
- Xtandi is an androgen receptor inhibitor- indicated to treat patients with CRPC and mCSPC
Click here to read full press release/ article | Ref: Pfizer | Image: Equities
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com